UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.
A study published in the Journal of Dermatology found that patients with psoriasis have an increased risk for cataracts and cataract surgery, with risks varying by treatment modality. The research was conducted by Yan-Jie Su from Taipei Veterans General Hospital in Taiwan.
An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.
Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.
A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.
Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.
Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.
A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.
Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.
An international multidisciplinary group of 31 experts coordinated by EBMT, ISCT, and JACIE has released updated consensus recommendations for using CAR T-cell therapy in patients with severe, treatment-refractory autoimmune diseases. The guidelines, originally released in 2024, include recommendations around optimizing safety.
Novartis agreed to pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, with the deal valued at up to $7.8 billion including milestones. The mRNA-based therapy targets autoimmune diseases.
Novartis will pay $500 million upfront and up to $7.3 billion in milestones to license an mRNA-based autoimmune therapy from China's Abogen Biosciences, marking one of the largest biotech deals involving a Chinese company.
Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.
Immunovant has discontinued development of IMVT-1402 for cutaneous lupus erythematosus after the anti-FcRn antibody failed to meet its primary endpoint in a proof-of-concept study of 57 patients. The company's stock fell 6% following the announcement.
A U.S. study published in Arthritis & Rheumatology found that only 0.8% of patients treated with avacopan for ANCA-associated vasculitis developed drug-induced liver injury, with liver enzyme elevations being uncommon. The findings come as the FDA considers revoking approval for the drug following earlier safety concerns.
Bristol Myers Squibb paused closely watched autoimmune drug research in early June after reports of life-threatening side effects and deaths, notifying regulators, researchers and patient advocacy groups.
Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.
Belgian-Dutch biotech argenx agreed to acquire Forte Biosciences for $2.2 billion in cash ($77 per share, an 86% premium to its VWAP since July 9), adding FB102, an anti-CD122 antibody in development for vitiligo and celiac disease, to its immunology pipeline.
The U.S. Food and Drug Administration has granted accelerated approval to Vera Therapeutics' drug TRUTAKNA for treating adult patients with primary IgA nephropathy, a potentially life-threatening chronic autoimmune kidney disease. The approval sent Vera's shares up 6.8% in afternoon trading.